![]() | Only 14 pages are availabe for public view |
Abstract Introduction Patients suffering from novel COVID-19 have varying liver function abnormalities. Liver injury necessitates a thorough examination and ongoing monitoring because it can be multifactorial and heterogeneous. Hepatic involvement in COVID-19 could be related to underlying liver disease, drugs used to treat COVID-19, a direct effect of the virus, or a complicated disease course in COVID-19. Aim of the Work This study aimed at studying liver enzymes abnormalities through different waves of COVID-19 and finding possible relations to disease severity. Methods This retrospective study included 521 patients diagnosed with COVID-19 infection based on PCR. We retrieved data from medical records of patients from Kasr Al-Ainy Hospitals, Cairo University, admitted from April 2020 to October 2021. They were divided according to the time of admission to the hospital in the four different waves. They were categorized according to disease severity. We collected medical data including patient’s demographics (age, gender, comorbidities), presenting symptoms (general, respiratory, GI), complications in the course of management, outcome, and relevant laboratory studies (blood indices, inflammatory markers, and liver enzymes) on the first day of admission and followed up after five days. Other baseline data included chest computed tomography (CT) findings were included as well. The outcome of the study patients was reported |